Ovid Therapeutics is a New York-based biopharmaceutical company using its BoldMedicine™ approach to focus exclusively on developing impactful medicines for patients and families living with rare neurological disorders.
Ovid’s drug candidate OV101 is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial of OV101 in adolescents with Angelman syndrome or Fragile X syndrome.
Ovid is also developing OV935 as part of a global collaboration with Takeda Pharmaceutical Company Limited for the treatment of certain types of rare epilepsies. A Phase 1b/2a trial is currently studying OV935 in adult patients with developmental and/or epileptic encephalopathy. Ovid is led by Jeremy M. Levin, who serves as the company’s chief executive offer and chairman of the board of directors.
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.